Using antibodies against Ki67 as a proliferation marker [26], we observed no significant differences in the mean percentage of proliferation control (28.7%) versus GPNMB/OA-expressing mammary tumors (25.1%) (Figure 2A). Here, MKI67 is linked to breast cancer.